MULTIPLE MYELOMA KNOWLEDGE CENTER

Get the Facts

Find what you need to know
in our brochures.

DOWNLOAD

Speak to an MMRF
nurse specialist

An MMRF nurse specialist can
guide you through your multiple
myeloma journey every step of the
way. Call Monday-Friday, 9-7 ET.

CALL NOW

What is Elotuzumab?

Elotuzumab, also known as HuLuc63, is a monoclonal antibody being developed by Bristol-Myers Squibb in collaboration with AbbVie. Elotuzumab binds to SLAMF7, also known as CS1, a substance that is on the surface of myeloma cells. This agent is given as an intravenous infusion.

The Multiple Myeloma Research Consortium (MMRC) has played a role in this drug’s development and is currently facilitating several trials evaluating elotuzumab in combination with other myeloma agents.